Last Updated 2016

vanderbilt-universtiy-medical-center v2
Vanderbilt’s personalized medicine program strives to be a leading international center in the transformation of medicine to focus on the individual. The mission includes support of discovery, translation and implementation science in the mechanisms of variable susceptibility to disease and drug responses to improve human health. This includes a focus on genomics as well as many other environmental and socio-cultural factors that drive susceptibility to disease and variable drug responses. The program operates from the Office of Personalized Medicine under Dan M. Roden, M.D., Assistant Vice-Chancellor for Personalized Medicine.
Scientific discovery remains the cornerstone for advancing an agenda in personalized medicine. Discoveries can be at the very basic cellular or molecular level, in whole animals, and in patients; moving discoveries from the bench to the bedside remains a high priority as well.
Vanderbilt has a longstanding commitment to personalized medicine that has included:

  • The development of a very large biobank linking DNA samples to de-identified patient records (BioVU)
  • The PREDICT project that embeds genetic information in patient electronic medical records to guide choice of drug and drug dosages
  • Advanced informatics capabilities including a research-receptive electronic medical record
  • Commitment to genomic research and genotyping platforms.

Vanderbilt is a site in three NIH networks: the Pharmacogenomics Research Network (PGRN); Integrated, Individualized, and Intelligent Prescribing (I³P) Network (IGNITE); and the Electronic Medical Records and Genomics Network (eMERGE).


Team: Josh Peterson, MD, MPH; Dan Roden, MD; Josh Denny MD, MS